Patent IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Simon C. Goodacre, et al. Int'l Appln. No. PCT/GB03/004677 Int'l Date Filed 29 October 2003 (29/10/2003) Serial No.: (To be assigned) Case No.: T1596P Filed April 15, 2005 SUBSTITUTED PYRIDO-PYRIDAZINE DERIVATIVES. For WHICH ENHANCE COGNITION VIA THE **GABA-A RECEPTORS** Commissioner for Patents Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE


DATE OF DEPOSIT

CLOCAL 15.205

EXPRESS MAIL NO. EL 9 P 9 5 8 76 90 4 8

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSED TO COMMISSIONER FOR PATENTS, PO. BOX 1450, ALBANDRIA, VIRGINIA 22313-1450.

MAILED BY ON 15, 2005



This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

V Fric Thies

Reg. No. 35,382

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-3904

Date: April 14, 2005

JC12 Rec'd PCT/PTC 1.75. APR 2005
SUBSTITUTE for PTO/SB/08A (08-03). Information Disclosure Statement by Applicant

			_	Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE			
	substitute for form 1449A/PTO			CON TE IF KNOWN			
	INFORMATION 1	DIS	CLOSURE	Application Number	10/531517		
١,	STATEMENT BY	A TD	DI ICANT	Filing Date	April 14, 2005		
	STATEMENT DI	AI	FLICANI	First Named Inventor	Simon C. Goodacre et al		
			,	Group Art Unit			
	(use as many sheets	as n	ecessary)	Examiner Name			
Sheet	1	of	1	Attorney Docket Number	T1596P		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
				-	*	

FOREIGN PATENT DOCUMENTS							
Examiner	Cite No.		Foreign Patent Document		Name of Patentee or Applicant	Date of Publication of	
Initials*		Office	Number	Kind Code (if known)	of Cited Document	Cited Document MM-DD-YYYY	
		WO 01 90108 Merck Sharp & Dohme		Merck Sharp & Dohme	11/29/2001		
			WO 03 006464		Merck Sharp & Dohme	01/23/2003	

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.